Natixis’s Pfizer PFE Stock Holding History

Natixis’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.7M	Sell	1,912,234 -3,717,590	-66%	-$99M	0.19%	75
2025 Q4	$140M	Buy	5,629,824 +2,303,716	+69%	+$58.1M	0.5%	25
2025 Q3	$84.7M	Buy	3,326,108 +1,429,812	+75%	+$35.3M	0.39%	41
2025 Q2	$46M	Sell	1,896,296 -909,940	-32%	-$21.2M	0.2%	71
2025 Q1	$70.1M	Sell	2,806,236 -2,470,160	-47%	-$64.6M	0.38%	42
2024 Q4	$140M	Buy	5,276,396 +3,461,074	+191%	+$93.9M	0.86%	22
2024 Q3	$52.5M	Buy	1,815,322 +417,584	+30%	+$12.2M	0.3%	63
2024 Q2	$39.1M	Sell	1,397,738 -1,479,163	-51%	-$40.7M	0.22%	75
2024 Q1	$79.8M	Buy	2,876,901 +1,059,436	+58%	+$29.4M	0.42%	45
2023 Q4	$52.3M	Buy	1,817,465 +773,030	+74%	+$23.4M	0.38%	56
2023 Q3	$34.6M	Sell	1,044,435 -168,528	-14%	-$5.96M	0.27%	85
2023 Q2	$44.5M	Sell	1,212,963 -132,004	-10%	-$5.14M	0.36%	56
2023 Q1	$54.9M	Sell	1,344,967 -1,686,404	-56%	-$72.8M	0.5%	42
2022 Q4	$155M	Buy	3,031,371 +276,405	+10%	+$13.3M	0.87%	21
2022 Q3	$121M	Buy	2,754,966 +329,888	+14%	+$16M	0.57%	25
2022 Q2	$126M	Buy	2,425,078 +972,608	+67%	+$49.6M	0.46%	21
2022 Q1	$75.2M	Sell	1,452,470 -36,805	-2%	-$1.91M	0.26%	81
2021 Q4	$87.3M	Sell	1,489,275 -1,471,285	-50%	-$72.9M	0.3%	54
2021 Q3	$127M	Sell	2,960,560 -2,839,815	-49%	-$126M	0.44%	34
2021 Q2	$227M	Buy	5,800,375 +4,414,933	+319%	+$172M	0.99%	14
2021 Q1	$50.2M	Sell	1,385,442 -3,228,887	-70%	-$115M	0.16%	130
2020 Q4	$170M	Buy	4,614,329 +593,867	+15%	+$21.8M	0.62%	31
2020 Q3	$140M	Buy	4,020,462 +3,380,359	+528%	+$119M	1.03%	15
2020 Q2	$19.9M	Sell	640,103 -2,894,246	-82%	-$98.3M	0.15%	122
2020 Q1	$109M	Buy	3,534,349 +1,880,101	+114%	+$64.1M	0.86%	25
2019 Q4	$61.1M	Buy	1,654,248 +97,192	+6%	+$3.46M	0.38%	65
2019 Q3	$53.1M	Sell	1,557,056 -4,731,556	-75%	-$172M	0.34%	72
2019 Q2	$258M	Buy	+6,288,612	New	+$250M	1.99%	6
2019 Q1	–	Sell	-4,034,667	Closed	-$166M	–	863
2018 Q4	$166M	Sell	4,034,667 -355,281	-8%	-$14.7M	1.37%	11
2018 Q3	$184M	Buy	4,389,948 +1,385,195	+46%	+$53.3M	1.06%	15
2018 Q2	$103M	Buy	3,004,753 +1,774,006	+144%	+$60.6M	0.55%	42
2018 Q1	$41M	Sell	1,230,747 -3,084,070	-71%	-$106M	0.25%	95
2017 Q4	$148M	Buy	4,314,817 +626,206	+17%	+$21.4M	1.14%	13
2017 Q3	$125M	Buy	3,688,611 +814,466	+28%	+$26.2M	1.15%	17
2017 Q2	$91.6M	Buy	2,874,145 +1,166,241	+68%	+$36.8M	1.04%	21
2017 Q1	$55.4M	Buy	1,707,904 +1,088,030	+176%	+$34.3M	0.69%	36
2016 Q4	$19.1M	Sell	619,874 -330,535	-35%	-$10.1M	0.2%	130
2016 Q3	$30.5M	Buy	950,409 +411,038	+76%	+$13.7M	0.35%	76
2016 Q2	$18M	Buy	+539,371	New	+$17.2M	0.34%	70
2016 Q1	–	Sell	-4,017,596	Closed	-$123M	–	353
2015 Q4	$123M	Buy	4,017,596 +235,458	+6%	+$7.41M	2.05%	10
2015 Q3	$113M	Sell	3,782,138 -58,022	-2%	-$1.86M	2.35%	5
2015 Q2	$122M	Buy	+3,840,160	New	+$125M	1.65%	10
2015 Q1	–	Sell	-2,369,042	Closed	-$70M	–	458
2014 Q4	$70M	Sell	2,369,042 -5,647,080	-70%	-$162M	0.97%	22
2014 Q3	$225M	Buy	8,016,122 +2,187,003	+38%	+$61.4M	3.47%	4
2014 Q2	$164M	Buy	5,829,119 +404,563	+7%	+$11.5M	1.97%	8
2014 Q1	$165M	Sell	5,424,556 -2,156,591	-28%	-$64.3M	2.15%	7
2013 Q4	$220M	Buy	7,581,147 +2,181,961	+40%	+$63.5M	1.89%	8
2013 Q3	$147M	Buy	5,399,186 +4,536,396	+526%	+$123M	1.57%	8
2013 Q2	$22.9M	Buy	+862,790	New	+$23.8M	0.33%	77

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Natixis's PFE Position: Q1 2026 in Review

Natixis reduced its Pfizer (PFE) stake by 66% in Q1 2026, selling an estimated $99M and leaving 1,912,234 shares worth $53.7M. The position accounts for 0.19% of the portfolio, ranked #75.

Natixis first reported a position in PFE in Q2 2013 and has held it in 49 quarters since. The position peaked at $258M in Q2 2019. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Natixis held 1,912,234 shares of Pfizer worth $53.7M as of Q1 2026.
Natixis sold 3,717,590 Pfizer shares in Q1 2026, an estimated $99M.
Pfizer made up 0.19% of Natixis's portfolio in Q1 2026, its #75 holding.
Natixis first reported a position in Pfizer in Q2 2013 and has held it in 49 quarters since.
Natixis's Pfizer position peaked at $258M in Q2 2019.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.